Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Common Equity (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Common Equity data on record, last reported at $212.4 million in Q4 2025.

  • For Q4 2025, Common Equity fell 34.71% year-over-year to $212.4 million; the TTM value through Dec 2025 reached $212.4 million, down 34.71%, while the annual FY2025 figure was $212.4 million, 34.71% down from the prior year.
  • Common Equity reached $212.4 million in Q4 2025 per MRVI's latest filing, down from $245.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $905.2 million in Q4 2022 and bottomed at $212.4 million in Q4 2025.
  • Average Common Equity over 5 years is $596.2 million, with a median of $633.5 million recorded in 2022.
  • Peak YoY movement for Common Equity: skyrocketed 252.42% in 2021, then plummeted 61.33% in 2025.
  • A 5-year view of Common Equity shows it stood at $545.4 million in 2021, then surged by 65.99% to $905.2 million in 2022, then dropped by 12.74% to $789.9 million in 2023, then crashed by 58.82% to $325.3 million in 2024, then plummeted by 34.71% to $212.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $212.4 million in Q4 2025, $245.4 million in Q3 2025, and $468.0 million in Q2 2025.